Centre for Haemato-Oncology

Welcome to the Centre for Haemato-Oncology, where our main mission is to find cures for haematologic malignancies. We are a centre of excellence in state-of-the-art research and clinical translation, which brings together internationally-recognised basic scientists with top clinical  academics. Our central aim is to understand the biology of leukaemias and lymphomas and harness this knowledge to identify new treatment strategies. Working closely together with the Haemato-oncology department at the St Bartholomew’s Hospital Cancer Centre we are uniquely well placed to implement our findings in clinical practice. Moreover, our Centre is embedded in Barts and The London School of Medicine and Dentistry, one of the UK’s top medical schools, thus offering excellent opportunities for multidisciplinary collaborations.

Our main research themes and their associated faculty include:

  1. Stem cell biology and normal haematopoiesis (Laboratories: Ficz, Ganuza, Kranc, Nguyen, Rouault-Pierre)
  2. Biology and therapeutic targeting of leukaemia (Laboratories: Gribben, Gallipoli, Kranc, Krysov, Nguyen, Riches, Rouault-Pierre, Wrench)
  3. Pathogenesis and treatment of lymphomas (Laboratories: Braun, Okosun, Riches)
  4. Improving immunotherapy in blood malignancies (Laboratories: Davies, Gribben, Le Dieu)

Contact us

Centre Lead: Professor John Gribben

Deputy Centre Lead: Professor Kamil Kranc

Lab Manager: Dr Rebecca Gresham

Centre Administrator: bci-ho-pa@qmul.ac.uk

3rd Floor, John Vane Science Centre,
Charterhouse Square,
London EC1M 6BQ

Recent Publications

    • A functional screen of RNA binding proteins identifies genes that promote or limit the accumulation of CD138+ plasma cells. Elife (2022) 11:e72313. PMID: 35451955
    • CITED2 coordinates key hematopoietic regulatory pathways to maintain the HSC pool in both steady-state hematopoiesis and transplantation. Stem Cell Reports (2021) S2213-6711(21)00498-7. PMID: 34715054
    • Adipocytes disrupt the translational programme of acute lymphoblastic leukaemia to favour tumour survival and persistence. Nature Communications (2021) 12(1):5507. PMID: 34535653
    • The mRNA m6A reader YTHDF2 suppresses proinflammatory pathways and sustains hematopoietic stem cell function. J Exp Med (2021) 218(3):e20200829. PMID: 33156926
    • Retinoic acid-responsive CD8 effector T-cells are selectively increased in IL-23-rich tissue in gastrointestinal GvHD. Blood (2020) blood.2020005170. PMID: 32905596
    • Clinical outcome of coronavirus disease 2019 in haemato-oncology patients. Br J Haematol (2020) bjh.16852. PMID: 32420609
    • Transition to naïve human pluripotency mirrors pan-cancer DNA hypermethylation. Nat Commun (2020) 11(1):3671. PMID: 32699299
    • Divide and Rule: Mitochondrial Fission Regulates Quiescence in Hematopoietic Stem Cells. Cell Stem Cell (2020) 26(3):299-301. PMID: 32142657
See more
  • IGHV sequencing reveals acquired N-glycosylation sites as a clonal and stable event during follicular lymphoma evolution. Blood (2020) 135(11):834-844. PMID: 31932843
  • Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy. Cell Metab (2020) 32(5):829-843.e9. PMID: 32966766
  • A randomised Phase II trial of Hydroxychloroquine and Imatinib versus Imatinib alone for patients with Chronic Myeloid Leukaemia in Major Cytogenetic Response with residual disease. Leukemia (2020) 34(7):1775-1786. PMID: 31925317
  • Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients. Blood (2020) blood.2020008824. PMID: 33113551
  • Clones assemble! The clonal complexity of blood during ontogeny and disease. Experimental Hematology (2020) 83:35-47. PMID: 32006606
  • The global clonal complexity of the murine blood system declines throughout life and after serial transplantation. Blood (2019) 133(18):1927-1942. PMID: 30782612
  • Targeting the RNA m6A reader YTHDF2 selectively compromises cancer stem cells in acute myeloid leukemia. Cell Stem Cell (2019) 25(1):137-148.e6. PMID: 31031138
  • Oncogenic Rag GTPase signaling enhances B cell activation and drives follicular lymphoma sensitive to pharmacological inhibition of mTOR. Nat Metab (2019) 1(8):775-789. PMID: 31579886
  • AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol (2019) 37(14):1188-1199. PMID: 30897038

Latest News

  • Dr Bela Wrench had a paper published in Nature Communications. The research identifies a new role for a group of cells called adipocytes in contributing to treatment resistance in a type of leukaemia. Find out more in our news story.
  • In recognition of Blood Cancer Awareness Month in September, Dr John Riches spoke about his role as a clinical scientist, combining medicine with blood cancer research. Read the Q&A article.
  • Dr Miguel Ganuza was selected by the American Society of Hematology (ASH) to receive the 2021 ASH Global Research Award to investigate how damaged blood stem cells escape the immune system to drive a process known as clonal haematopoiesis. Find out more.
  • Miguel Ganuza is the recipient of a Career Development Award from the Medical Research Council. The project will look at 'Genetic identification and functional dissection of the bone marrow niches that support haematopoietic stem cells and leukaemic stem cells.' Read our news story to find out more.

Areas of focus

Acute myeloid leukaemia
FL cropped
Acute lymphoblastic leukaemia
DLBCL immunofluorescence - PMCH FITC
Chronic lymphocytic leukaemia
Follicular lymphoma - H&E
Stem Cell Biology
Hodgkins - EBV in situ hydribisation - blue
Vessels (CD31) CLL/SLL


Research in the Centre for Haemato-Oncology is kindly funded by Cancer Research UK, Blood Cancer UK, Barts Charity, The Kay Kendall Leukaemia Fund and Medical Research Council.